Connect with us

News

Canada launches medical cannabis helpline

Published

on

A new helpline line has been launched in Canada, in response to a growing number of enquiries about how to use medical cannabis.

From Monday 31 August a new cannabis information line, which has been designed by doctors, will be available to all Canadians.

Cannalogue’s CBDHelp is a free telephone information line for individuals or caregivers looking for general guidance on medical cannabis including recommended uses and applications for cannabidiol (CBD).

Based in Toronto, Cannalogue is a rapidly emerging healthcare technology company that received Health Canada’s first direct-to-sales licence for medical cannabis.

Staffed by medical professionals, CBDHelp was developed as a way to help better educate consumers about the potential benefits of medical cannabis in treating a variety of conditions including anxiety, stress, difficulty sleeping, gastrointestinal issues and chronic pain, among others.

Dr Mohan Cooray, president and CEO of Cannalogue said: “We launched CBDHelp in response to the growing number of inquiries we were receiving about how and when to use medical cannabis.”

The use of medical cannabis has been legal in Canada since 2001 and in 2018 it became the second country to legalise marijuana for recreational use.

Dr Cooray added: “There continues to be a tremendous amount of misinformation and stigma associated with cannabis use and we wanted to help Canadians understand the benefits of cannabinoids such as CBD as an alternative to harmful and often addictive pharmaceutical therapies.”

CBDHelp is available Monday-Friday from 9am – 5pm EST by calling toll free at 1-833-CANNA-4-U (1-833-226-6248). Call backs can be arranged at www.cannalogue.ca/cbdhelp.

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 PP Intelligence Ltd.